获得性癌症酪氨酸激酶抑制剂耐药性：活性氧作为关键决定因素。 - Suppr

Acquired cancer tyrosine kinase inhibitor resistance: ROS as critical determinants.

作者信息

Bekeschus Sander

机构信息

ZIK plasmatis, Leibniz Institute for Plasma Science and Technology (INP), Felix-Hausdorff-Str. 2, 17489, Greifswald, Germany.

出版信息

Signal Transduct Target Ther. 2021 Dec 24;6(1):437. doi: 10.1038/s41392-021-00844-5.

DOI:10.1038/s41392-021-00844-5

PMID:34952897

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8709854/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5375/8709854/19a8217f927f/41392_2021_844_Fig1_HTML.jpg

相似文献

Acquired cancer tyrosine kinase inhibitor resistance: ROS as critical determinants.获得性癌症酪氨酸激酶抑制剂耐药性：活性氧作为关键决定因素。

Signal Transduct Target Ther. 2021 Dec 24;6(1):437. doi: 10.1038/s41392-021-00844-5.

Targeting Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer by Inducing Epidermal Growth Factor Receptor Degradation via Methionine 790 Oxidation.通过甲硫氨酸790氧化诱导表皮生长因子受体降解来靶向治疗酪氨酸激酶抑制剂耐药的非小细胞肺癌

Antioxid Redox Signal. 2016 Feb 10;24(5):263-79. doi: 10.1089/ars.2015.6420. Epub 2015 Dec 14.

Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics.用于表皮生长因子受体基因突变阳性非小细胞肺癌的酪氨酸激酶抑制剂：治疗学最新进展

J Oncol Pharm Pract. 2016 Jun;22(3):461-76. doi: 10.1177/1078155215577810. Epub 2015 Apr 8.

Continuation of epidermal growth factor receptor tyrosine kinase inhibitor treatment prolongs disease control in non-small-cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors.表皮生长因子受体酪氨酸激酶抑制剂治疗的持续进行可延长对EGFR酪氨酸激酶抑制剂获得性耐药的非小细胞肺癌的疾病控制时间。

Oncotarget. 2015 Sep 22;6(28):24904-11. doi: 10.18632/oncotarget.4570.

Combination treatment with erlotinib and ampelopsin overcomes erlotinib resistance in NSCLC cells via the Nox2-ROS-Bim pathway.厄洛替尼与蛇葡萄素联合治疗通过Nox2-ROS-Bim途径克服非小细胞肺癌细胞中的厄洛替尼耐药性。

Lung Cancer. 2017 Apr;106:115-124. doi: 10.1016/j.lungcan.2017.02.009. Epub 2017 Feb 14.

Acquired resistance of non-small cell lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors.非小细胞肺癌对表皮生长因子受体酪氨酸激酶抑制剂的获得性耐药

Respir Investig. 2014 Mar;52(2):82-91. doi: 10.1016/j.resinv.2013.07.007. Epub 2013 Aug 30.

Cigarette smoke extract induces EGFR-TKI resistance via promoting EGFR signaling pathway and ROS generation in NSCLC cell lines.香烟烟雾提取物通过促进非小细胞肺癌细胞系中的表皮生长因子受体（EGFR）信号通路和活性氧（ROS）生成来诱导EGFR酪氨酸激酶抑制剂（TKI）耐药。

Lung Cancer. 2017 Jul;109:109-116. doi: 10.1016/j.lungcan.2017.05.011. Epub 2017 May 13.

ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers.ROS1蛋白酪氨酸激酶抑制剂在治疗ROS1融合蛋白驱动的非小细胞肺癌中的应用

Pharmacol Res. 2017 Jul;121:202-212. doi: 10.1016/j.phrs.2017.04.022. Epub 2017 Apr 30.

Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer.后续化疗可逆转获得性酪氨酸激酶抑制剂耐药，并恢复晚期非小细胞肺癌对酪氨酸激酶抑制剂的反应。

BMC Cancer. 2011 Mar 2;11:90. doi: 10.1186/1471-2407-11-90.

Multiple Acquired Resistance Mutations of the ALK Tyrosine Kinase Domain after Sequential Use of ALK Inhibitors.序贯使用ALK抑制剂后ALK酪氨酸激酶结构域的多重获得性耐药突变

J Thorac Oncol. 2017 May;12(5):e49-e51. doi: 10.1016/j.jtho.2017.01.009.

引用本文的文献

CTBP2 contributes to cisplatin resistance in lung adenocarcinoma by inhibiting generation of reactive oxygen species.CTBP2通过抑制活性氧的产生促进肺腺癌对顺铂的耐药性。

Transl Cancer Res. 2024 Apr 30;13(4):1695-1706. doi: 10.21037/tcr-23-2135. Epub 2024 Apr 15.

Single cell lineage tracing reveals clonal dynamics of anti-EGFR therapy resistance in triple negative breast cancer.单细胞谱系追踪揭示了三阴性乳腺癌中抗 EGFR 治疗耐药性的克隆动态。

Genome Med. 2024 Apr 11;16(1):55. doi: 10.1186/s13073-024-01327-2.

Oxidized Proteins Differentially Affect Maturation and Activation of Human Monocyte-Derived Cells.氧化蛋白对人单核细胞来源细胞的成熟和激活有差异影响。

Cells. 2022 Nov 18;11(22):3659. doi: 10.3390/cells11223659.

Safety of Anti-Angiogenic Drugs in Pediatric Patients with Solid Tumors: A Systematic Review and Meta-Analysis.抗血管生成药物在实体瘤儿科患者中的安全性：一项系统评价和荟萃分析。

Cancers (Basel). 2022 Oct 28;14(21):5315. doi: 10.3390/cancers14215315.

本文引用的文献

Cycling cancer persister cells arise from lineages with distinct programs.循环肿瘤干细胞由具有不同特性的细胞谱系产生。

Nature. 2021 Aug;596(7873):576-582. doi: 10.1038/s41586-021-03796-6. Epub 2021 Aug 11.

Arsenene-mediated multiple independently targeted reactive oxygen species burst for cancer therapy.砷烯介导的多种独立靶向活性氧爆发用于癌症治疗。

Nat Commun. 2021 Aug 6;12(1):4777. doi: 10.1038/s41467-021-24961-5.

ROS from Physical Plasmas: Redox Chemistry for Biomedical Therapy.物理等离子体中的活性氧簇：用于生物医学治疗的氧化还原化学。

Oxid Med Cell Longev. 2019 Oct 8;2019:9062098. doi: 10.1155/2019/9062098. eCollection 2019.

The Redox Code.氧化还原密码

Antioxid Redox Signal. 2015 Sep 20;23(9):734-46. doi: 10.1089/ars.2015.6247. Epub 2015 Jun 1.

Molecular mechanisms for the regulation of Nrf2-mediated cell proliferation in non-small-cell lung cancers.Nrf2 介导的非小细胞肺癌细胞增殖调控的分子机制。

Oncogene. 2012 Nov 8;31(45):4768-77. doi: 10.1038/onc.2011.628. Epub 2012 Jan 16.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Acquired cancer tyrosine kinase inhibitor resistance: ROS as critical determinants.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献检索

文件翻译

深度研究

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献